// App-Quantinova.ai

TPS11109 : The DETECT Study Program: Personalized treatment in advanced breast cancer based on circulating tumor cells (CTCs).

Researchers

Presenter

  • Amelie Schramm

Principal Investigators

  • Thomas W. P. Friedl

  • Susanne Albrecht

  • Bahriye Aktas

  • Klaus Pantel

  • Franziska Meier-Stiegen

  • Wolfgang Janni

  • Elisabeth Katharina Trapp

  • Peter A. Fasching

  • Florin-Andrei Taran

  • Andreas D. Hartkopf

  • Andreas Schneeweiss

  • Volkmar Mueller

  • Tanja N. Fehm

  • Jens Bodo Huober

  • Brigitte Kathrin Rack

Medical Centers

  • Department of Gynecology and Obstetrics Heinrich-Heine-University Dusseldorf, Duesseldorf, Germany

  • Universitatsklinikum Ulm, Ulm, Germany

  • Heidelberg University Hospital, Heidelberg, Germany

  • University Hospital of Essen, Essen, Germany

  • University of Ulm, Ulm, Germany

  • Comprehensive Cancer Center, Erlangen, Germany

  • I. Universitaetsfrauenklinik, Hebertshausen, GermanyInstitute of Tumor Biology, Campus Forschung, University Hospital Hamburg-Eppendorf, Hamburg, GermanyUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Department of Gynecology and Obstetrics University Ulm, Ulm, Germany

  • University Hospital, Duesseldorf, Germany

  • Universitatsklinikum Ulm, Ulm, Germany

  • Department of Gynecology and Obstetrics Ludwig-MaximiliansUniversity, Munich, Germany

  • Department of Gynecology and Obstetrics, University of Tuebingen, Tuebingen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Everolimus

  • Pertuzumab

  • Lapatinib

  • Eribulin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • NCT02344472

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved